TICKERNOMICS Sign up
Last Update: 2024-12-27 15:29:57
BioNexus Gene Lab Corp ( BGLC ) https://www.bionexusgenelab.com
0.24USD
Sector:
Basic Materials
Industry:
Specialty Chemicals
Country:
Malaysia
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-54.10%
BGLC
SPY
32.66%
-98.98%
BGLC
SPY
108.59%
BGLC
0.00%
SPY
302.52%
BGLC
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
4.17
2.33
0.27
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-4.42
0.45
0.44
-31.03
0.00
-0.94
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-50.85
12.41
-25.84
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-41.36
-30.23
0.00
Other Earnings and Cash Flow Stats:
BioNexus Gene Lab Corp ( BGLC ) Net Income TTM ($MM) is -0.94
BioNexus Gene Lab Corp ( BGLC ) Operating Income TTM ($MM) is -0.90
BioNexus Gene Lab Corp ( BGLC ) Owners' Earnings Annual ($MM) is 0.00
BioNexus Gene Lab Corp ( BGLC ) Current Price to Owners' Earnings ratio is 0.00
BioNexus Gene Lab Corp ( BGLC ) EBITDA TTM ($MM) is -0.84
BioNexus Gene Lab Corp ( BGLC ) EBITDA Margin is -25.84%
Capital Allocation:
BioNexus Gene Lab Corp ( BGLC ) has paid 0.00 dividends per share and bought back -1.193293 million shares in the past 12 months
BioNexus Gene Lab Corp ( BGLC ) has increased its debt by 0.169806 million USD in the last 12 months
Capital Structure:
BioNexus Gene Lab Corp ( BGLC ) Interest-bearing Debt ($MM) as of last quarter is 0
BioNexus Gene Lab Corp ( BGLC ) Annual Working Capital Investments ($MM) are -1
BioNexus Gene Lab Corp ( BGLC ) Book Value ($MM) as of last quarter is 9
BioNexus Gene Lab Corp ( BGLC ) Debt/Capital as of last quarter is 2%
Other Balance Sheet Stats:
BioNexus Gene Lab Corp ( BGLC ) has 2 million in cash on hand as of last quarter
BioNexus Gene Lab Corp ( BGLC ) has 1 million of liabilities due within 12 months, and long term debt 0 as of last quarter
BioNexus Gene Lab Corp ( BGLC ) has 17 common shares outstanding as of last quarter
BioNexus Gene Lab Corp ( BGLC ) has 0 million USD of preferred stock value
Academic Scores:
BioNexus Gene Lab Corp ( BGLC ) Altman Z-Score is 1.90 as of last quarter
BioNexus Gene Lab Corp ( BGLC ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
BioNexus Gene Lab Corp ( BGLC ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of BioNexus Gene Lab Corp ( BGLC ) for the amount of $ on
43.72% of BioNexus Gene Lab Corp ( BGLC ) is held by insiders, and 0.88% is held by institutions
BioNexus Gene Lab Corp ( BGLC ) went public on 2020-09-16
Other BioNexus Gene Lab Corp ( BGLC ) financial metrics:
FCF:-2.48
Unlevered Free Cash Flow:3.10
EPS:-0.30
Operating Margin:-50.85
Gross Profit Margin:12.41
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-57.32
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About BioNexus Gene Lab Corp ( BGLC ) :
BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.